Creo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Creo Medical develops minimally invasive electrosurgical devices designed to improve patient outcomes. With its innovative CROMA and Kamaptive technologies, Creo Medical is setting new standards in precision and flexibility for clinicians across a range of surgical procedures. This funding has been sought to mitigate the completion risk of its recently announced sale of a 51% controlling interest in the group’s European subsidiary, Creo Medical Europe. It also aims to provide balance sheet strength for future growth, as Creo Medical continues to roll out its defined medtech strategy.
Oaklins Cavendish, one of Oaklins’ member firms in the UK, served as advisor to Creo Medical on the transaction.
Sprechen Sie mit dem Deal-Team
Transaktionen
Tekova Oyj has completed a technical listing on the Nasdaq First North Growth Market Finland
Tekova Oyj has successfully completed a technical listing (IPO) on the Nasdaq First North Growth Market Finland. This transaction marks a significant milestone in the company’s growth strategy, enhancing its visibility and access to capital markets.
Mehr erfahrenDie Bayer AG hat eine Übernahmevereinbarung mit Cara Care geschlossen
Die Bayer AG, bekannt für vielfältige Innovationen in den Bereichen Gesundheit und Life Science, hat die Übernahme von Cara Care (HiDoc Technologies GmbH) vereinbart, für die im Oktober 2024 ein Insolvenzverfahren eröffnet worden war. Cara Care, eine innovative digitale Gesundheitsplattform und offizielle DiGA, passt perfekt zu Bayers strategischem Fokus auf digitale Gesundheit und die Erweiterung seines Lösungsportfolios. Der Abschluss der Transaktion wird für das Frühjahr 2025 erwartet.
Mehr erfahrenDuke Capital Limited has completed a fundraising
Duke Capital Limited has completed a successful fundraise, securing US$29.8 million (£23.5 million) through a placing and retail offer on the Alternative Investment Market (AIM). This milestone will further enable Duke Capital to continue its innovative approach to alternative financing solutions for small and medium enterprises (SMEs) across the UK and Europe.
Mehr erfahren